Sunday, February 23, 2020 5:39:03 PM
Fortunately, just the opposite should be true for psoriasis in the case of a topical cream for it. In a matter or days or weeks improvement should be clear. The FDA may want a number of months to prove it's durable, but it won't take years, to even decades as some oncology products due. Then it should be possible to permit the earnings from the psoriasis cream to fund the MM trial, at least in part. A substantially higher stock price could certainly fund it with some dilutive funding as well. Investors may not like dilution, but when the share price reaches high single digit to low double digit dollars, I don't believe investors will mind.
I believe there is other good news on many of the products the company is working on. Once patent approvals come it, the trial process for the conditions they're directed at may be longer than psoriasis, but it's nowhere near as long, or expensive as going after MM or other cancers.
I suspect that once more is known about patent, and trials of the cream, the likelihood of a BP partnering with OWCP will be far greater, and that too will greatly take care of funding for the companies many products.
Gary
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM